Navigation Links
SARS vaccine shows promise in Animal Testing

SARS, or severe acute respiratory syndrome, is a coronavirus. Similar viruses infect the pigs and other animals. It emerged in southern China in late 2002 and spread to more than two dozen countries on four continents before it was contained last summer. // More than 8,000 people worldwide were sickened, and at least 774 died.Civet cats and other mongoose-like animals that are sold in live food markets in southern China are suspected of spreading SARS to humans although the original source of the virus has not been determined.

Researchers say mice immunized with an experimental SARS vaccine were protected against the deadly respiratory disease Results from an accelerated federal research program show the vaccine prompted an immune response in the mice and dramatically reduced the level of the virus in the lungs of some mice.

However the results lead to mixed opinions , some researchers say more experiments are needed to determine if it will work in humans. Some scientists not connected with the study said the results were encouraging, but should not be overstated. No DNA vaccine has yet been shown to effectively treat any viral disease and the approach is still unproven compared to conventional vaccines.

Vaccines are normally made from dead or weakened viruses and work by mobilizing the body's immune system to build defenses by showing it what the targeted virus looks like. That approach is used every year, for example, to develop flu shots to combat emerging strains of influenza.

But the SARS vaccine was made from a small piece of genetic material from the virus called a plasmid. It biochemically locks onto a specific protein on the outer surface of the virus. This alerts the body's immune system to launch a counterattack against the invading virus.

Scientists tested two versions of the DNA vaccine in 15 mice over a six-week period. The vaccines differed in how much genetic material scientists removed from the origin
'"/>




Page: 1 2

Related medicine news :

1. New hope for cancer victims – will vaccine cure the deadly bug
2. New vaccine helps allergy and asthma patients
3. Man against HIV – new vaccine ready for human trials
4. New vaccine helps allergy and asthma patients
5. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
6. HIV did not arise from polio vaccine
7. Double impact vaccine
8. High Demand for a child vaccine
9. A new vaccine for leukemia
10. Shortage of MMR vaccine
11. Anthrax vaccine produced

Post Your Comments:
(Date:11/9/2009)... Fast food chains are ofte...sity. A recent poll by Fitness.com.au however find...ulder the responsibility. , ... food chains, and video games were behind Australi...Dad are more than just innocent bystanders. A rece...
(Date:11/9/2009)..., The National Comprehensive Cancer Network (NC...ent that details a draft paradigm for near-term co... upon existing data. The document introduces the N...sensus-based process that compares the risk-versus...d in the NCCN Clinical Practice Guidelines in Onco...
(Date:11/9/2009)..., CHICAGO, Nov. 9 Highlighting ...titutions with advanced entertainment and digital ...casing its latest Long-Term Care and Hospital Grad...and Services for the Aging 2009 annual meeting and...s booth, the new line of "HealthView(TM)" Long-Ter...
(Date:11/9/2009)...tudy didn,t answer question of why this is so, how...s) -- After a lumpectomy, women with very dense br...he affected breast, a new study shows. , Breast... risk of developing breast cancer, and experts hav...sociated with an increased risk of cancer recurren...
(Date:11/9/2009)..., CAMBRIDGE, Mass., Nov. 9 Ab...d capabilities in delivering emergency management ...y awarded contracts to support the work of the Fed...f Regional Operations, the National Commission on ...itan Area Transit Authority (WMATA). The value of...
Breaking Medicine News(10 mins):Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 2Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 3Health News:NCCN Posts Comparative Effectiveness White Paper for Public Comment 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 2Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 3Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 4Health News:LG Electronics' New Line of HDTVs for Long-Term Care Facilities Signal Transition From Resident-Owned to Facility-Owned HDTVs 5Health News:Dense Breasts Raise Risk of Cancer Recurrence 2Health News:Dense Breasts Raise Risk of Cancer Recurrence 3Health News:Abt Associates Expands Emergency Management Support Services To the Federal Government and Washington Metropolitan Area Transit Authority 2
... HMS (Nasdaq: HMSY ) today announced that it had...hborhood Health Providers and Optima Health, a Sen... to its managed care portfolio. HMS will provide t...ge not previously known for its Medicaid members, ...
...Feb. 10 Zeus, Inc. is pleased to introduce its en...ccessible via http://www.zeusinc.com . , , With ... user-friendly resource for comprehensive informat...mation into four categories listed on the site,s h...
... New Epocrates Survey Reveals Patients May M... San Mateo, CA (PRWEB) Feb...to make more difficult economic choices than ever ...ake cutbacks on medications that could be harmful ...
...northern Illinois to use a new, cutting edge diagn...mprove patient care and outcomes. , , WOBURN, Mas...ounced OSF Saint Anthony Medical Center in Rockfor...physicians, pharmacists and nurses improve care an...
...., Feb. 10 Arete Therapeutics Inc. today,announce... AR9281, an orally-,administered soluble epoxide h...treatment of type 2 diabetes. S-EH is an enzyme in...81 Phase II clinical trial program breaks new grou...
... decline in procedure volume rate shows signs of s...ure volume up 48% , , Provides near-term financ...FirstCall/ -- LCA-Vision Inc. (Nasdaq: LCAV ),...and 12 months ended December 31, 2008. , , Fourt...
Other Medicine News:Health News:HMS Awarded New Contracts for Managed Care Services 2Health News:Doctors Fear Patients Not Filling Prescriptions 2Health News:Doctors Fear Patients Not Filling Prescriptions 3Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 2Health News:OSF Saint Anthony Medical Center Implements PNA FISH(R) Tests to Help Provide Best Care for Patients with Bloodstream Infections 3Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 3Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 16
(Date:11/9/2009)..., Pa., Nov. 9 ARmark Authenticatio...today an alliance in the development and introduct...ntication technology that incorporates microscopic... coatings of solid oral dosage forms (SODFs) to pr...on exclusive rights to market ARmark,s micro-tags ...
(Date:11/9/2009)... Oregon, November 9 Bend Research ...nce in applying innovative pharmaceutical,technolo...ientific and,technical problems, announced today t...x Pharmaceuticals Incorporated, a global biotechno..., Through this new collaboration, Vertex will ...
(Date:11/9/2009)...ov. 9 PAREXEL Internatio... biopharmaceutical services provider, today announ...lities for early phase clinical development throug... manufactures and distributes electrocardiogram (E...XEL is using Mortara Instrument,s Surveyor Telemet...
Breaking Medicine Technology:ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 2ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance 3Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 2Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 2PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 3PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 4PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument 5Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 13493 1Sinovac to Host Conference Call to Report 2009 Second Quarter Financial Results 13493 2Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly 242 Billion in 2018 13490 1Biologic Agents Will Drive the Systemic Lupus Erythematosus Drug Market to More Than Quadruple to Nearly 242 Billion in 2018 13490 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 1BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 2BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 3BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels 13488 4
...al Meeting -, - Conference call to be hosted toda..., Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRG...ng Phase II,trial of CR011-vcMMAE, an antibody-dru...of patients with unresectable Stage III or Stage I...ator, and Professor and Chairman of,the Department...
...ented at AASLD annual meeting, Pivotal Phase III ...ose,who failed prior treatment, SAN FRANCISCO, No...day reported that a planned interim analysis of a,...gational oral hepatitis C,protease inhibitor, in c...ly increased sustained virologic response (SVR) ra...
Other Medicine Technology:CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 2Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 3Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 4Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 5Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 6Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 7Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 8Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 9Boceprevir Phase II Study Showed High Rate of Sustained Response With 28- and 48-Week Regimens in Genotype 1 Treatment-Naive Hepatitis C Patients 10
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
Moore Hyperopic Flap Conformer, 48 Diopter
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
...gulation (ECP) is a surgical approach to glaucoma ...lized laser application. The ciliary body (which p...from the anterior or posterior segment, through th...asily and accurately identified utilizing endoscop...
Medicine Products: